XERS Xeris Pharmaceuticals Inc
Price (delayed)
$5.15
Market cap
$792.79M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.37
Enterprise value
$992.62M
Xeris Pharmaceuticals Inc. is a specialty pharmaceutical company delivering innovative solutions to simplify the experience of administering important therapies that people rely on every day around the world.
Highlights
The company's revenue rose by 24% YoY and by 8% QoQ
The gross profit has grown by 23% YoY and by 9% from the previous quarter
The debt has grown by 18% YoY
XERS's quick ratio is down by 7% since the previous quarter and by 4.3% year-on-year
Key stats
What are the main financial stats of XERS
Market
Valuations
Earnings
Shares outstanding
153.94M
Market cap
$792.79M
Enterprise value
$992.62M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
3.72
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.89
Revenue
$203.07M
Gross profit
$166.24M
Operating income
-$33.65M
Net income
-$54.84M
EBIT
-$26.62M
EBITDA
-$13.99M
Free cash flow
-$37.85M
Per share
Balance sheet
Liquidity
EPS
-$0.37
EPS diluted
-$0.37
Free cash flow per share
-$0.26
Book value per share
-$0.2
Revenue per share
$1.38
TBVPS
$1.37
Total assets
$323.06M
Total liabilities
$352.68M
Debt
$271.45M
Equity
-$29.62M
Working capital
$67.22M
Debt to equity
-9.17
Current ratio
1.67
Quick ratio
1.12
Net debt/EBITDA
-14.28
Margins
Efficiency
Dividend
EBITDA margin
-6.9%
Gross margin
81.9%
Net margin
-27%
Operating margin
-16.6%
Return on assets
-16.7%
Return on equity
N/A
Return on invested capital
-8.2%
Return on capital employed
-12%
Return on sales
-13.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
XERS stock price
How has the Xeris Pharmaceuticals stock price performed over time
Intraday
1.38%
1 week
-9.81%
1 month
34.46%
1 year
146.41%
YTD
51.92%
QTD
-6.19%
Financial performance
How have Xeris Pharmaceuticals's revenue and profit performed over time
Revenue
$203.07M
Gross profit
$166.24M
Operating income
-$33.65M
Net income
-$54.84M
Gross margin
81.9%
Net margin
-27%
Xeris Pharmaceuticals's operating margin has increased by 38% YoY and by 31% from the previous quarter
The net margin has grown by 29% YoY and by 20% from the previous quarter
The operating income has grown by 26% since the previous quarter and by 24% year-on-year
The company's revenue rose by 24% YoY and by 8% QoQ
Growth
What is Xeris Pharmaceuticals's growth rate over time
Valuation
What is Xeris Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
3.72
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.89
XERS's EPS is up by 18% year-on-year and by 16% since the previous quarter
XERS's equity is down by 4.6% since the previous quarter
XERS's price to sales (P/S) is 75% more than its last 4 quarters average of 2.1 but 31% less than its 5-year quarterly average of 5.3
The company's revenue rose by 24% YoY and by 8% QoQ
Efficiency
How efficient is Xeris Pharmaceuticals business performance
XERS's ROS is up by 42% year-on-year and by 31% since the previous quarter
The return on invested capital has increased by 40% year-on-year and by 28% since the previous quarter
The return on assets rose by 13% since the previous quarter and by 13% year-on-year
Dividends
What is XERS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for XERS.
Financial health
How did Xeris Pharmaceuticals financials performed over time
The total assets is 8% less than the total liabilities
XERS's quick ratio is down by 7% since the previous quarter and by 4.3% year-on-year
XERS's current ratio is down by 7% since the previous quarter
The debt to equity has soared by 73% YoY and by 4.2% from the previous quarter
The debt has grown by 18% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.